Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D, receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas

European Journal of Nuclear Medicine

Volumn 26, Issue 1, 1999, Pages 46-50

  De Herder, W W ^a   Reijs, A E M ^b   De Swart, J ^b   Kaandorp, Y ^b   Lamberts, S W J ^b   Krenning, E P ^b   Kwekkeboom, D J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Dopamine receptors; Iodine 123 epidepride; Iodine 123 IBZM; Pituitary; Single photon emission tomography

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; EPIDEPRIDE; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; HUMAN; HYPOPHYSIS; HYPOPHYSIS ADENOMA; INTERMETHOD COMPARISON; MALE; PROLACTINOMA; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADENOMA; BENZAMIDES; BRAIN; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA; PYRROLIDINES; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033031157     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050358     Document Type: Article

References (24)

1. 1. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumour shrinkage. Endocr Rev 1992; 13: 220-240.
2. 2. Bevan JS, Burke CW. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol 1986; 25: 561-572.
3. 3. Koga M, Nakao H, Arao M, et al. Demonstration of specific dopamine receptors on human pituitary adenomas. Acta Endocrinol 1987; 114: 595-602.
4. 4. Serri O, Marchisio AM, Collu R, Hardy J, Somma M. Dopaminergic binding sites in human pituitary adenomas other than prolactinomas. Horm Res 1984; 19: 97-102.
5. 3H]Spiperone binding to human anterior pituitaries and pituitary adenomas secreting prolactin, growth hormone, and adrenocorticotropic hormone. J Clin Endocrinol Metab 1980; 50: 387-391.
6. 6. Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989; 69: 500-509.
7. 7. Kwekkeboom DJ, Lamberts SW. Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma. Clin Endocrinol 1992; 36: 171-176.
8. 11C-N-methylspiperone. J Comput Assist Tomogr 1986; 10: 175-180.
9. 9. Bergstrom M, Muhr C, Lundberg PO, Langstrom B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 1991; 32: 610-615.
10. 10. Pirker W, Brucke T, Riedl M, et al. Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors. J Neural Transm Gen Sect 1994; 97: 235-244.
11. 11. Scillitani A, Dicembrino F, Di FP, et al. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. J Clin Endocrinol Metab 1995; 80: 2523-2525.
12. 2 receptor radioligand. Clin Endocrinol 1996; 45: 755-767.
13. 123I-methoxybenzamide with hormone levels and tumour size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab 1998; 83: 248-252.
14. 2 receptors in basal ganglia and cortex of human brain. J Pharmacol Exp Ther 1991; 257: 1253-1263.
15. 125I]epidepride. Brain Res 1993; 609: 237-243.
16. 125I]epidepride. Eur J Pharmacol 1992; 227: 443-445.
17. 2 receptor imaging. J Nucl Med 1996; 37: 1589-1591.
18. 123I]epidepride: characterization of uptake in the human brain. J Neural Transm Gen Sect 1995; 101: 95-103.
19. 2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT. J Nucl Med 1996; 37: 1931-1937.
20. 20. Ichise M, Ballinger JR. SPECT imaging of dopamine receptors. J Nucl Med 1996; 37: 1591-1595.
21. 123I]IBZM) in rat and human brain. Int J Rad Appl Instrum [13] 1991; 18: 837-846.
22. 125I]-IBZM): a potential imaging ligand for D-2 dopamine receptors in SPECT. Life Sci 1988; 42: 2097-2104.
23. 125I]iodo-2-methoxybenzamide hydrochloride, a new selective radioligand for dopamine D-2 receptors. J Med Chem 1988; 31: 2027-2033.
24. 123I-IBZM using the rotating gamma-camera. Nucl Med Commun 1991; 12: 687-697.